- Home
- SWIN vs RVPH Comparison
SWIN vs RVPH Comparison
Compare SWIN & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWIN
- RVPH
- Stock Information
- Founded
- SWIN 2017
- RVPH 2006
- Country
- SWIN Hong Kong
- RVPH United States
- Employees
- SWIN N/A
- RVPH N/A
- Industry
- SWIN
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- SWIN
- RVPH Health Care
- Exchange
- SWIN Nasdaq
- RVPH Nasdaq
- Market Cap
- SWIN 214.1M
- RVPH 26.6M
- IPO Year
- SWIN 2023
- RVPH N/A
- Fundamental
- Price
- SWIN $3.93
- RVPH $0.46
- Analyst Decision
- SWIN
- RVPH Strong Buy
- Analyst Count
- SWIN 0
- RVPH 5
- Target Price
- SWIN N/A
- RVPH $9.00
- AVG Volume (30 Days)
- SWIN 208.1K
- RVPH 3.2M
- Earning Date
- SWIN 08-21-2025
- RVPH 08-13-2025
- Dividend Yield
- SWIN N/A
- RVPH N/A
- EPS Growth
- SWIN N/A
- RVPH N/A
- EPS
- SWIN N/A
- RVPH N/A
- Revenue
- SWIN $3,316,000.00
- RVPH N/A
- Revenue This Year
- SWIN $29.79
- RVPH N/A
- Revenue Next Year
- SWIN $54.60
- RVPH N/A
- P/E Ratio
- SWIN N/A
- RVPH N/A
- Revenue Growth
- SWIN N/A
- RVPH N/A
- 52 Week Low
- SWIN $1.16
- RVPH $0.30
- 52 Week High
- SWIN $4.40
- RVPH $4.28
- Technical
- Relative Strength Index (RSI)
- SWIN 62.05
- RVPH 46.82
- Support Level
- SWIN $3.70
- RVPH $0.44
- Resistance Level
- SWIN $3.99
- RVPH $0.53
- Average True Range (ATR)
- SWIN 0.35
- RVPH 0.04
- MACD
- SWIN -0.03
- RVPH 0.02
- Stochastic Oscillator
- SWIN 93.02
- RVPH 56.07
About SWIN Solowin Holdings
Solowin Holdings Ltd is an investor-focused, versatile securities brokerage company in Hong Kong. It offers a wide spectrum of products and services through its secure one-stop electronic platform. It is engaged in providing securities-related services, investment advisory services, and asset management services to customers. The operations were organized into four reportable segments: Corporate Finance Services, Wealth Management Services, Asset Management Services and Virtual Assets. It derives maximum revenue from Wealth Management Services.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.